The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GRN300–001: Phase 1/1B evaluation of the safety, pharmacokinetics, and efficacy of GRN-300, a salt-inducible kinase inhibitor, alone and in combination with paclitaxel, in recurrent ovarian, primary peritoneal, and fallopian tube cancers.
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Millennium (Inst); NCCN (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Parexel International, LLC (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Vaccibody (Inst)
 
Amir A. Jazaeri
Stock and Other Ownership Interests - Avenge Bio
Honoraria - Gerson Lehrman Group; Guidepoint Global; Mosaic Research Management
Consulting or Advisory Role - Agenus; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; integrity Continuing Education; Iovance Biotherapeutics; Macrogenics; NuProbe; twoXAR
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); ZIOPHARM Oncology (Inst)
 
Zhen Lu
Patents, Royalties, Other Intellectual Property - Pending patent application No. 63164308. (Inst)
 
Markus Peter
Employment - Eisai; Greenfire Bio
Stock and Other Ownership Interests - Merck/Schering Plough
 
Stephan Wade Morris
Employment - Biomea Fusion; Greenfire Bio
Leadership - Biomea Fusion; Greenfire Bio
Stock and Other Ownership Interests - Biomea Fusion; Greenfire Bio
Consulting or Advisory Role - Biomea Fusion
Patents, Royalties, Other Intellectual Property - Various Anaplastic Lymphoma Kinase (ALK)-related royalties
 
Robert C. Bast
Consulting or Advisory Role - OncoTex
Research Funding - Green3Bio (Inst); InterVenn Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - Fujirebio Diagnostics